Advanced HCC
5 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| KD6001 in Combination With Anti-PD-1 Antibody±Bevacizumab in Patients With Advanced HCC and Other Solid Tumors (NCT05906524) | Shanghai Kanda Biotechnology Co., Ltd. | 2024-04-15 |
| Lenalidomide to Reverse Drug Resistance After First-line Treatment of Advanced HCC (NCT05831969) | Shenyang Tenth People's Hospital | 2023-06-05 |
| Efficacy of Target - Immunotherapy and XELOX Chemotherapy for Advanced HCC (NCT06818097) | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2021-10-01 |
| KN046 Combined With Ningatinib in the Treatment of Advanced Hepatocellular Carcinoma (NCT04601610) | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 2021-06-07 |
| Elimination of CD4+CD25+ Regulatory T Cells in Patients With Hepatocellular Carcinoma (NCT00396682) | Hannover Medical School | 2007-02-01 |
Track Advanced HCC automatically
Every clearance here is in the API, with alerts when new ones post.